Business Description
Entera Bio Ltd
ISIN : IL0011429839
Total Employee Number:
22Description
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 26.61 | |||||
Equity-to-Asset | 0.37 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -41.5 | |||||
3-Year EBITDA Growth Rate | 17.9 | |||||
3-Year EPS without NRI Growth Rate | 17.8 | |||||
3-Year FCF Growth Rate | 28.1 | |||||
3-Year Book Growth Rate | -11.4 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 32.15 | |||||
9-Day RSI | 45.53 | |||||
14-Day RSI | 52.27 | |||||
3-1 Month Momentum % | 121.48 | |||||
6-1 Month Momentum % | 115.11 | |||||
12-1 Month Momentum % | 54.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.98 | |||||
Quick Ratio | 8.98 | |||||
Cash Ratio | 5.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17 | |||||
Shareholder Yield % | -2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -26092.86 | |||||
OCF Margin % | -25926.19 | |||||
ROE % | -134.03 | |||||
ROA % | -99.4 | |||||
ROIC % | -190.25 | |||||
3-Year ROIIC % | 22.29 | |||||
ROC (Joel Greenblatt) % | -206.94 | |||||
ROCE % | -94.27 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2905 | |||||
PB Ratio | 19.37 | |||||
Price-to-Tangible-Book | 19.37 | |||||
EV-to-EBIT | -34.17 | |||||
EV-to-EBITDA | -34.25 | |||||
EV-to-Revenue | 11716.6 | |||||
EV-to-Forward-Revenue | 1844.65 | |||||
EV-to-FCF | -44.9 | |||||
| Price-to-Net-Current-Asset-Value | 20.75 | |||||
Earnings Yield (Greenblatt) % | -2.93 | |||||
FCF Yield % | -2.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ENTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Entera Bio Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.042 | ||
| EPS (TTM) ($) | -0.35 | ||
| Beta | 0.3064 | ||
| 3-Year Sharpe Ratio | 0.84 | ||
| 3-Year Sortino Ratio | 1.96 | ||
| Volatility % | 104.16 | ||
| 14-Day RSI | 52.27 | ||
| 14-Day ATR ($) | 0.267677 | ||
| 20-Day SMA ($) | 3.023 | ||
| 12-1 Month Momentum % | 54.92 | ||
| 52-Week Range ($) | 0.91001 - 4.2 | ||
| Shares Outstanding (Mil) | 173.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Entera Bio Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Entera Bio Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 73 days | ||
| Canaccord Genuity 46th Annual Growth Conference | 2026-08-12 13:00 | 3.00 (+0.67%) | ||
| Second quarter earnings results for 2026 | 2026-08-07 | 2.82 (+1.08%) | ||
| General meeting for 2026 | 2026-07-14 08:00 | 1.64 (-0.61%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 1.37 (+9.60%) | ||
| Key Opinion Leader Virtual Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 | 2026-04-20 11:00 | 1.28 (+4.07%) | ||
| Annual report for 2025 | 2026-03-27 | 1.03 (-9.65%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-27 | 1.03 (-9.65%) | ||
| Guidance call for 2026 | 2026-03-11 10:40 | 1.49 (+8.76%) | ||
| 8th Annual Evercore ISI Healthcare Conference | 2025-12-03 09:10 | 2.22 (-1.77%) |
Show
Entries
Entera Bio Ltd Frequently Asked Questions
What is Entera Bio Ltd(ENTX)'s stock price today?
The current price of ENTX is $2.91. The 52 week high of ENTX is $4.20 and 52 week low is $0.91.
When is next earnings date of Entera Bio Ltd(ENTX)?
The next earnings date of Entera Bio Ltd(ENTX) is 2026-11-13 Est..
Does Entera Bio Ltd(ENTX) pay dividends? If so, how much?
Entera Bio Ltd(ENTX) does not pay dividend.
Press Release
Articles on Entera Bio Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers